NCT00861042View on ClinicalTrials.gov

An Open-label follow-on Trial to Assess the Long-term Safety and Efficacy of Oral SPM 927 in Subjects With Diabetic Neuropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

December 31, 2004

Study Completion Date

March 31, 2005

Conditions
Painful Diabetic Neuropathy
Interventions
DRUG

SPM927/Lacosamide

SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation

Sponsors

Lead Sponsor

UCB Pharma
All Listed Sponsors
lead

UCB Pharma

INDUSTRY

NCT00861042 - An Open-label follow-on Trial to Assess the Long-term Safety and Efficacy of Oral SPM 927 in Subjects With Diabetic Neuropathy | Biotech Hunter | Biotech Hunter